Seattle Genetics Inc. (SGEN)

Name: Seattle Genetics Inc. (SGEN)
Uploaded: 2011-08-21
Duration: 1 min 33 s
Description: Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings

karmastock Follow 2

Date: 2011. 08. 21.

Shares: 0 Forwards: 0 Embeds: 1

Category: people & vlogs

Add to list

To Quicklist To Favorites

Embed video

Width

Height

Embed code:

<iframe width="640" height="480" src="//videa.hu/player?v=9ZDC74RcyXP1BB5G" allowfullscreen="allowfullscreen" webkitallowfullscreen="webkitallowfullscreen" mozallowfullscreen="mozallowfullscreen" frameborder="0"></iframe>

Create GIF

Time:

99:99 sec

Resolution:

Crop: Custom 16:9 4:3 Original

Speed (fps): 2 10 20

Create snapshot

New snapshot Download (png) Download (jpg)

Report video

Reason for rejection:

Please provide the following details precisely:

Your full legal name, which typically consists of a surname and a given name, as it appears on a government-issued ID. Videa cannot process the request until it has this information.

The authorized person's email address.

Specify the subject of the grievance and the facts indicating a probable infringement.

I make the following legal declaration:

• I declare that I am acting in good faith, and that the information and statements contained in the notification are accurate and complete.

After verifying the request, Videa will initiate the video removal process.

REPORT

Date: 2011. 08. 21.

Shares: 0

Forwards: 0

Embeds: 1

Tags: adcetris • hodgkin • nasdaq:sgen • nationalcancerinstitute • seattlegenetics • sgen • usfda

Category: people & vlogs

Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings